venture capital

Abingworth raises $356M to invest in late-stage drug development
Abingworth raises $356M to invest in late-stage drug development
BioPharma Dive
venture capital
funding
Abingworth
drug development
Flag link:
After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma
After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma
Fierce Biotech
biotech
funding
venture capital
Flag link:
'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
Fierce Biotech
Europe
funding
venture capital
Forbion
BioGeneration Ventures
Medicxi
Flag link:
‘We’re in the 1999 of the internet era’: a16z’s Julie Yoo on fintech’s potential and the digital health market
‘We’re in the 1999 of the internet era’: a16z’s Julie Yoo on fintech’s potential and the digital health market
BioPharma Dive
fintech
venture capital
digital health
Flag link:
Foundery, a new biotech venture firm, sets out to speed early immune drug research
Foundery, a new biotech venture firm, sets out to speed early immune drug research
BioPharma Dive
Foundery
immunology
R&D
venture capital
funding
Flag link:
Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
Stat
biotech
funding
venture capital
The Column Group
Flag link:
Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
Stat
biotech
funding
venture capital
Flag link:
Reed Jobs, son of Steve Jobs, takes the wraps off a $200 million venture fund that will back new cancer treatments
Reed Jobs, son of Steve Jobs, takes the wraps off a $200 million venture fund that will back new cancer treatments
TechCrunch
venture capital
Emerson Collective
oncology
Steve Jobs
Reed Jobs
Flag link:
Westlake raises $450M in latest biotech venture fund
Westlake raises $450M in latest biotech venture fund
BioPharma Dive
Westlake Village Biopartners
venture capital
funding
Flag link:
Lilly, Novo, BMS return to boost BGV's largest European biotech fund yet
Lilly, Novo, BMS return to boost BGV's largest European biotech fund yet
Fierce Biotech
Eli Lilly
Novo Holdings
Bristol Myers Squibb
venture capital
funding
BGV
Europe
Flag link:
Women left out of VC club fight for their identity, pulling each other up one by one
Women left out of VC club fight for their identity, pulling each other up one by one
Fierce Biotech
venture capital
biotech
funding
Norwest Venture Partners
women
Flag link:
Slump in medtech VC activity continues as inflation keeps investors on the sidelines
Slump in medtech VC activity continues as inflation keeps investors on the sidelines
BioPharma Dive
Medtech
funding
venture capital
Flag link:
Orbital shows 2023’s venture funding scene is far from stratospheric
Orbital shows 2023’s venture funding scene is far from stratospheric
EP Vantage
RNA
funding
venture capital
Altos Labs
CureVac
EQRx
Hasten Biopharmaceutic
Orbital Therapeutics
Sana Biotechnology
Suzhou Abogen Biosciences
TORL BioTherapeutics
Flag link:
NYBC Ventures Launches $50M Fund to Accelerate Innovations in Blood and Cellular Therapies
NYBC Ventures Launches $50M Fund to Accelerate Innovations in Blood and Cellular Therapies
Yahoo/Businesswire
venture capital
NYBC Ventures
Flag link:
Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitor
Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitor
Fierce Biotech
venture capital
Joe Jimenez
Aditum Bio
autoimmune disease
Flag link:
A lean first quarter for venture-backed developers
A lean first quarter for venture-backed developers
EP Vantage
funding
venture capital
ArriVent Biopharma
Flare Therapeutics GSK
Hemab
Flag link:
Cure Ventures unveils inaugural $350M fund with focus on diligent seed rounds to de-risk new science
Cure Ventures unveils inaugural $350M fund with focus on diligent seed rounds to de-risk new science
Fierce Biotech
Cure Ventures
biotech
funding
venture capital
Flag link:
What M&A slowdown? Buyers circle GreenLight Biosciences, Egitis Therapeutics
What M&A slowdown? Buyers circle GreenLight Biosciences, Egitis Therapeutics
Fierce Biotech
M&A
GreenLight Biosciences
Egitis Therapeutics
venture capital
Flag link:
Biotech startups face ‘Series A cliff’ as venture capital stays cautious
Biotech startups face ‘Series A cliff’ as venture capital stays cautious
BioPharma Dive
funding
venture capital
Series A
Series B
Flag link:
Return of the megaround: Is biotech back from the brink?
Return of the megaround: Is biotech back from the brink?
Fierce Biotech
Rapport Therapeutics
Noema Pharma
Bicara Therapeutics
funding
venture capital
Flag link:

Pages